The treatment of
bronchial asthma with
QVAR (
hydrofluoroalkane-134a BDP; 3M
Pharmaceuticals, St. Paul, MN, USA) is usually conducted without an inhalation assistance device. However, Japanese patients who experience difficulty in coordinating activation with inspiration of inhaled
steroid drugs are instructed on the use of such a device. We therefore examined the necessity of using an inhalation assistance device (INSPIR-EASE, IE) and its effect on quality of life (QOL) in the treatment of patients with
bronchial asthma taking
QVAR. Hence, lung function and QOL associated with taking
QVAR plus IE or
QVAR alone were examined by a cross-over method in 44
bronchial asthma patients (STEP 2 or 3) over 20 years of age. In all patients, lung function tests conducted 12 weeks after start of treatment indicated significant improvements of forced expiratory volume in 1 second (FEV1) with
QVAR alone compared with
QVAR plus IE (p < 0.05). In patients less than 70 years of age, significant improvements of forced vital capacity (FVC) and
nitric oxide (NO) were also observed with
QVAR alone compared with
QVAR plus IE (p < 0.05). Examination of QOL the Living with
Asthma Questionnaire indicated that medication usage was significantly improved with
QVAR alone compared with
QVAR plus IE. Significant improvement of FEV1 was observed with
QVAR alone compared with
QVAR plus IE, and additionally in patients less than 70 years of age improvement of FVC and NO was also marked. This study confirmed the usefulness of
QVAR alone in patients with
bronchial asthma.